Bio‑Thera Solutions, Ltd. (SHA: 688177) announced that its golimumab biosimilar, BAT2506, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) — the first golimumab biosimilar approved in China, completing a trifecta of approvals across China, the United States, and Europe for the company’s golimumab franchise.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Biosimilar marketing approval |
| Product | BAT2506 (golimumab biosimilar) |
| Reference Product | Golimumab (Simponi), originally developed by Johnson & Johnson |
| Indications | Rheumatoid arthritis; ankylosing spondylitis |
| Approval Date | 5 Nov 2026 |
| Distinction | First golimumab biosimilar approved in China |
| Development Standard | Developed in accordance with biosimilar guidelines issued by NMPA, U.S. FDA, and European EMA |
Drug Profile & Mechanism of Action
- Molecule: Golimumab, a TNF‑α‑targeting monoclonal antibody, now delivered as Bio‑Thera’s biosimilar BAT2506.
- Mechanism: Binds specifically with high affinity to both soluble and transmembrane human TNF‑α, preventing TNF‑α from engaging its receptors and thereby neutralizing TNF‑α‑driven inflammation.
- Reference Product Heritage: Simponi is approved globally for multiple indications, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis.
- Global‑Grade Development: BAT2506 was developed to meet the biosimilar requirements of three major regulatory authorities (NMPA, FDA, EMA) — a tri‑jurisdictional quality standard supporting its multi‑market filings.
Global Regulatory Footprint – Golimumab Franchise
| Date | Region / Agency | Brand Name(s) | Indications Approved |
|---|---|---|---|
| Feb 2026 | Europe – EMA | Gotenfia | Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, juvenile idiopathic arthritis |
| May 2026 | United States – FDA | IMMGOLIS | In combination with methotrexate: moderately to severely active RA in adults; moderately to severely active ulcerative colitis in adults |
| May 2026 | United States – FDA | IMMGOLIS INTRI | In combination with methotrexate: moderately to severely active RA in adults |
| Nov 2026 | China – NMPA | BAT2506 | Rheumatoid arthritis; ankylosing spondylitis |
The U.S. approvals in May 2026 made IMMGOLIS and IMMGOLIS INTRI the first golimumab biosimilars approved in the United States. To date, Bio‑Thera’s golimumab has been approved for marketing in China, the United States, and Europe.
Market Impact & Outlook
- First‑Mover Advantage in China: As the first golimumab biosimilar on the Chinese market, BAT2506 enters ahead of any domestic competitors in the TNF‑α inhibitor class for this reference molecule.
- Large Patient Base: RA and AS affect substantial patient populations in China, where demand for affordable biologic therapy continues to grow as biologics gain broader insurance and hospital access.
- Tri‑Market Franchise: With approvals spanning China, the U.S., and Europe under multiple brand names (BAT2506, Gotenfia, IMMGOLIS, IMMGOLIS INTRI), Bio‑Thera has built one of the most geographically complete golimumab biosimilar portfolios globally.
- Biosimilar Execution Proof Point: Back‑to‑back EMA, FDA, and NMPA approvals within a single year validate the company’s development and regulatory strategy across the world’s three largest pharmaceutical markets.
- Next Catalysts: Commercial launch and tender/hospital access progress in China, alongside continued indication expansion leveraging the reference product’s global label footprint.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization timelines, market access, and competitive expectations for BAT2506 and Bio‑Thera’s golimumab franchise. Actual results may differ due to risks including launch execution, pricing and reimbursement dynamics, competitive biosimilar entry, and manufacturing and supply considerations.-Fineline Info & Tech
